JP7395194B2 - 外因性および内因性アルブミンを放射性標識するためのイメージング剤 - Google Patents

外因性および内因性アルブミンを放射性標識するためのイメージング剤 Download PDF

Info

Publication number
JP7395194B2
JP7395194B2 JP2021503750A JP2021503750A JP7395194B2 JP 7395194 B2 JP7395194 B2 JP 7395194B2 JP 2021503750 A JP2021503750 A JP 2021503750A JP 2021503750 A JP2021503750 A JP 2021503750A JP 7395194 B2 JP7395194 B2 JP 7395194B2
Authority
JP
Japan
Prior art keywords
optionally substituted
group
metal complex
cancer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021503750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532123A (ja
JPWO2020023247A5 (https=
JP2021532123A5 (https=
Inventor
フェリクス クラッツ，
アジャアジャ， ハーリド アブ
アナ ワルネッケ，
フリーデリーケ イー． ノルマン，
シュテファン ダーヴィト ケスター，
フェルナンデス， ハビエル ガルシア
ララ ペス，
シュテフェン ダウム，
ヨハネス パル マグヌソン，
セルゲイ チェルへジャ，
ガラン， パトリシア ぺレス
フェデリコ メダ，
Original Assignee
センチュリオン バイオファーマ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センチュリオン バイオファーマ コーポレイション filed Critical センチュリオン バイオファーマ コーポレイション
Publication of JP2021532123A publication Critical patent/JP2021532123A/ja
Publication of JPWO2020023247A5 publication Critical patent/JPWO2020023247A5/ja
Publication of JP2021532123A5 publication Critical patent/JP2021532123A5/ja
Application granted granted Critical
Publication of JP7395194B2 publication Critical patent/JP7395194B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2021503750A 2018-07-23 2019-07-16 外因性および内因性アルブミンを放射性標識するためのイメージング剤 Active JP7395194B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862702081P 2018-07-23 2018-07-23
US62/702,081 2018-07-23
PCT/US2019/042025 WO2020023247A1 (en) 2018-07-23 2019-07-16 Imaging agents for radiolabeling exogenous and endogenous albumin

Publications (4)

Publication Number Publication Date
JP2021532123A JP2021532123A (ja) 2021-11-25
JPWO2020023247A5 JPWO2020023247A5 (https=) 2022-07-26
JP2021532123A5 JP2021532123A5 (https=) 2022-07-26
JP7395194B2 true JP7395194B2 (ja) 2023-12-11

Family

ID=69181921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021503750A Active JP7395194B2 (ja) 2018-07-23 2019-07-16 外因性および内因性アルブミンを放射性標識するためのイメージング剤

Country Status (11)

Country Link
US (1) US20210353783A1 (https=)
EP (1) EP3826685A4 (https=)
JP (1) JP7395194B2 (https=)
KR (1) KR20210035213A (https=)
CN (1) CN112823028A (https=)
AU (1) AU2019309242B2 (https=)
BR (1) BR112021001314A2 (https=)
CA (1) CA3107328A1 (https=)
IL (1) IL280308B2 (https=)
MX (1) MX2021000926A (https=)
WO (1) WO2020023247A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3263646A1 (en) * 2022-07-29 2024-07-18 Curium Us Llc [177lu] lutetium-psma l&t composition, kit, method of making, and method of using thereof
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514081A (ja) 2003-02-04 2006-04-27 シエーリング　アクチエンゲゼルシヤフト エナンチオマー純粋な（４Ｓ，８Ｓ）−及び（４Ｒ，８Ｒ）−４−ｐ−ニトロベンジル−８−メチル−３，６，９−トリアザ−３Ｎ，６Ｎ，９Ｎ−トリカルボキシメチル−１，１１−ウンデカン二酸及びそれらの誘導体、それらの製造方法並びに医薬品の製造のためのそれらの使用
WO2008074960A2 (fr) 2006-12-14 2008-06-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094950A (en) * 1988-06-07 1992-03-10 Nihon Medi-Physics Co., Ltd. Diethylenetriamine pentaacetic acid derivatives
US20050233307A1 (en) * 2002-09-12 2005-10-20 Kyle Gee Site-specific labeling of affinity tags in fusion proteins
US20040208828A1 (en) * 2003-02-04 2004-10-21 Lutz Lehmann Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic acid and derivatives thereof, process for their production and use for the production of pharmaceutical agents
KR100695744B1 (ko) * 2005-05-03 2007-03-19 한국원자력연구소 디티피에이(ｄｔｐａ) 유도체 및 이들을 이용한 금속 착화물, 이들을 포함하는 방사선원 및 조영제
WO2008070384A2 (en) * 2006-11-06 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of preparing macromolecular contrast agents and uses thereof
EP2630971B8 (en) * 2012-02-21 2017-12-13 Vergell Medical S.A. Combinations of albumin-based drug delivery systems

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514081A (ja) 2003-02-04 2006-04-27 シエーリング　アクチエンゲゼルシヤフト エナンチオマー純粋な（４Ｓ，８Ｓ）−及び（４Ｒ，８Ｒ）−４−ｐ−ニトロベンジル−８−メチル−３，６，９−トリアザ−３Ｎ，６Ｎ，９Ｎ−トリカルボキシメチル−１，１１−ウンデカン二酸及びそれらの誘導体、それらの製造方法並びに医薬品の製造のためのそれらの使用
WO2008074960A2 (fr) 2006-12-14 2008-06-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux conjugues, utilisables a des fins therapeutiques, et/ou a titre d'agent de diagnostic et/ou d'imagerie et leur procede de preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Analytical chemistry，83，2011年，9123-9130

Also Published As

Publication number Publication date
EP3826685A4 (en) 2022-04-06
MX2021000926A (es) 2021-03-31
JP2021532123A (ja) 2021-11-25
EP3826685A1 (en) 2021-06-02
WO2020023247A1 (en) 2020-01-30
IL280308B2 (en) 2024-09-01
KR20210035213A (ko) 2021-03-31
CN112823028A (zh) 2021-05-18
AU2019309242A1 (en) 2021-03-11
BR112021001314A2 (pt) 2021-05-11
US20210353783A1 (en) 2021-11-18
CA3107328A1 (en) 2020-01-30
IL280308A (en) 2021-03-01
AU2019309242B2 (en) 2025-05-29
IL280308B1 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
ES2675320T3 (es) Dendrímeros dirigidos a PSMA
JP2024028742A (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
CN108290924B (zh) 肽硫脲衍生物、含有其的放射性同位素标记化合物、和含有该化合物作为活性成分的用于治疗或诊断前列腺癌的药物组合物
CA3090812A1 (en) Chemical conjugates of evans blue derivatives and their use as radiotherapy and imaging agents for targeting prostate cancer
ES2980073T3 (es) Composición novedosa de diagnóstico por imágenes y usos de la misma
ES2990974T3 (es) Conjugados de folato de entidades fijadoras de albúmina
KR20200123148A (ko) Fap 억제제
US9217009B2 (en) Version of FDG detectable by single-photon emission computed tomography
ES2703627T3 (es) Análogos de folato/antifolato marcados con 18F
AU2016380151A1 (en) Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy
US20250025582A1 (en) Ligands and their use
JP7395194B2 (ja) 外因性および内因性アルブミンを放射性標識するためのイメージング剤
Moon et al. Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting
CA2978304A1 (en) Methods of treating cancer with a psma ligand-tubulysin compound
RU2819907C2 (ru) Средства визуализации для меченного радиоактивным изотопом экзогенного и эндогенного альбумина
Makris et al. Synthesis, characterization, and biological evaluation of new biotinylated 99mTc/Re‐tricarbonyl complexes
KR20250065366A (ko) 방사성핵종 조성물 및 이를 이용한 종양세포 검출 방법
HK1255215B (en) Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy
WO2008064040A2 (en) Methods and compositions using chelator-antibody conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220715

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231121

R150 Certificate of patent or registration of utility model

Ref document number: 7395194

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350